|
|
Each tablet contains
Composition
Gatifloxacin.....................................................................200
mg
Ornidazole......................................................................500
mg Indications
Respiratory tract infections like lung abscess, aspiration
pneumonia, empyema and bronchiectasis.
ENT infections like chronic sinusitis, chronic suppurative otitis
media, cholesteatoma and mastoiditis.
Dermatological infections like cellulitis, breast and other
cutaneous abscesses, gangrene and decubitus ulcers. Orofacial and
dental infections.
Surgical wound infections.
Gynaecological infections including
Description
Gatifloxacin, a new type of quinolone antibiotic, has been
approved by the U.S. Food and Drug Administration for indications
including the treatment of community-acquired respiratory tract
infections (RTIs). It was designed with a unique 8-methoxy
structure that appears to enhance bactericidal action and decrease
the rate of the development of resistance of gram-positive
bacteria.
Quinolones rapidly inhibit DNA synthesis by promoting cleavage of
bacterial DNA in the DNA-enzyme complexes of DNA gyrase and type
IV topoisomerase, resulting in rapid bacterial death. As a general
rule, gram-negative bacterial activity correlates with inhibition
of DNA gyrase, and gram-positive bacterial activity corresponds
with inhibition of DNA type IV topoisomerase.
Quinolones inhibit two specific enzymes, DNA gyrase and DNA
topoisomerase IV, which aid in bacterial DNA replication. FACTIVE
displays strong binding affinity at both of these target sites,
which helps maintain high in vitro potency against resistant S
pneumoniae. This dual targeting with FACTIVE is achievable at
therapeutic drug levels.
The antimicrobial activity of ornidazole is due to the reduction
of the nitro group to a more reactive amine that attacks microbial
DNA, brings about loss of helical structure of DNA and subsequent
DNA breakage thus inhibiting further synthesis and causing
degradation of existing DNA.
Contraindications
Gatifloxacin is contraindicated in persons with a history of
hypersensitivity to gatifloxacin or any member of the quinolone
class of antimicrobial agents.
Ornidazole is contraindicated in persons with a history of
hypersensitivity ornidazole and other imidazoles.
Warnings and precautions
Special precautions are required in case of ataxia, vertigo,
mental confusion and patients with neurological diseases. There is
need for adjustment of dosage and dosage interval in patients with
hepatic impairment. Modification of the usual dosage is not
necessary in patients of renal failure however, additional post
haemodialysis dose may be required in patients undergoing this
procedure.
Dosage
The recommended dosage for Gatimin-OZ tablets is described below.
Doses of Gatimin-OZ are administered once every 24 hours.
Presentations
10 tablets
|
Quality
